{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=5",
    "query": {
      "intervention": "Placebo SC Injection",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 833,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T20:02:33.317Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06750289",
      "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Asthma"
      ],
      "interventions": [
        {
          "name": "ICS-LABA",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "benralizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo for Benralizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-28",
      "completion_date": "2026-09-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 20,
      "location_summary": "Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06750289"
    },
    {
      "nct_id": "NCT07590193",
      "title": "A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "AMG 127",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 162,
      "start_date": "2026-06-11",
      "completion_date": "2027-10-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 2,
      "location_summary": "Lake Forest, California • Aventura, Florida",
      "locations": [
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07590193"
    },
    {
      "nct_id": "NCT05567393",
      "title": "A Study of TAK-951 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-951 Placebo",
          "type": "DRUG"
        },
        {
          "name": "TAK-951",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2019-03-07",
      "completion_date": "2020-11-02",
      "has_results": true,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567393"
    },
    {
      "nct_id": "NCT05421598",
      "title": "Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 437,
      "start_date": "2022-06-30",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • Los Angeles, California • San Jose, California + 18 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05421598"
    },
    {
      "nct_id": "NCT01488708",
      "title": "On Open-Label Study in Participants With Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Connective Tissue Disease",
        "Autoimmune Disease"
      ],
      "interventions": [
        {
          "name": "LY2127399",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1518,
      "start_date": "2012-01",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 1,
      "location_summary": "Irving, Texas",
      "locations": [
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488708"
    },
    {
      "nct_id": "NCT04159415",
      "title": "Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low-Dose REGN4461",
          "type": "DRUG"
        },
        {
          "name": "High-dose REGN4461",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-01-07",
      "completion_date": "2024-09-24",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04159415"
    },
    {
      "nct_id": "NCT06611163",
      "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Genital Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tildrakizumab 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2025-03-21",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 36,
      "location_summary": "Anaheim, California • Encinitas, California • Encino, California + 30 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06611163"
    },
    {
      "nct_id": "NCT06834347",
      "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Rhinosinusitis With Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Itepekimab (SAR440340)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mometasone furoate nasal spray (MFNS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2025-02-12",
      "completion_date": "2027-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 21,
      "location_summary": "Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834347"
    },
    {
      "nct_id": "NCT04773678",
      "title": "Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Persistent Asthma"
      ],
      "interventions": [
        {
          "name": "CBP-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Connect Biopharm LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 322,
      "start_date": "2021-05-11",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 39,
      "location_summary": "Tucson, Arizona • Huntington Beach, California • Lancaster, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04773678"
    },
    {
      "nct_id": "NCT05724199",
      "title": "A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Rocatinlimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 746,
      "start_date": "2023-02-21",
      "completion_date": "2024-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-28T20:02:33.317Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05724199"
    }
  ]
}